topic

297 Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers
Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, E Andres Houseman, Shan Zhong, Jaegil Kim, David Turner, Laura Johnson, Ioanna Eleftheriadou, Jenna Tress, Aisha Hasan, Victoria Chiou, Naimish Pandya, John Glod, Dejka Araujo, Warren Chow, Mihaela Druta, George Demetri, Brian Van Tine, Sandra D’Angelo

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A181-A182; DOI: 10.1136/jitc-2020-SITC2020.0297
169 Microfluidics cell squeezing enables human PBMCs as drivers of antigen-specific CD8 T responses across broad range of antigens for diverse clinical applications
Michael Maloney, Scott Loughhead, Amritha Ramakrishnan, Carolyne Smith, Anita Venkitaraman, Christian Yee, Miye Jacques, Defne Yarar, Armon Sharei, Howard Bernstein, Kelan Hlavaty, Melissa Myint, Katherine Seidl

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A183; DOI: 10.1136/jitc-2020-SITC2020.0169
302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma
Georgia Beasley, Nellie Farrow, Karenia Landa, Maria Angelica Seilm, Sin-Ho Jung, Darell Bigner, Andrea True Kelly, Smita Nair, Matthias Gromeier, April Salama

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A185; DOI: 10.1136/jitc-2020-SITC2020.0302
303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results
Diwakar Davar, Arivarasan Karunamurthy, Douglas Hartman, Richelle DeBlasio, Joe-Marc Chauvin, Quanquan Ding, Ornella Pagliano, Amy Rose, John Kirkwood, Hassane Zarour

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A185-A186; DOI: 10.1136/jitc-2020-SITC2020.0303
305 Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples
Tyler Hether, Tim Howes, Christine Spencer, Travis Hollman, Jason Reeves, Danny Wells, Claire Friedman, Theresa LaVallee, Jedd Wolchok, Sarah Warren

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A187; DOI: 10.1136/jitc-2020-SITC2020.0305
309 The role of tumor-draining lymph nodes in the tuning of systemic T cell immunity by CTLA-4 blockade is revealed by local delivery of tremelimumab in early-stage melanoma: data from a Phase-I trial
Jessica Notohardjo, Kim van Pul, Anita Stam, Dafni Chondronasiou, Sinead Lougheed, Petrousjka van den Tol, Karin Jooss, Ronald Vuylsteke, Alfons van den Eertwegh, Tanja de Gruijl

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A190; DOI: 10.1136/jitc-2020-SITC2020.0309
311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma
Chantal Saberian, Rodabe Amaria, Cara Haymaker, Marie Andree Forget, Roland Bassett, Isabella Glitza, Gregory Lizee, Cassian Yee, Jeniffer McQuade, Michael Wong, Hussein Tawbi, Sapna Patel, Adi Diab, Michael Davies, Patrick Hwu, Chantale Bernatchez

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A191-A192; DOI: 10.1136/jitc-2020-SITC2020.0311
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
Manish Patel, Jason Luke, Erika Hamilton, Bartosz Chmielowski, George Blumenschein, Hedy Kindler, Shakeela Bahadur, Cesar Santa-Maria, Janine Koucheki, Jichao Sun, Sanjeev Kaul, Francine Chen, Xiaoyu Zhang, John Muth, Patrick Kaminker, Paul Moore, Bradley Sumrow, Susanna Ulahannan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A193; DOI: 10.1136/jitc-2020-SITC2020.0313
316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A
Aurelien Marabelle, Christiane Jungels, Johann De Bono, Norbert Vey, Martin Wermke, Elena Garralda, Aude de Gassart, Patrick Brune, Emmanuel Valentin, Marina Iché, Daniel Olive, Paul Frohna

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A194-A195; DOI: 10.1136/jitc-2020-SITC2020.0316
318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007
Timothy A Yap, Mallika Dhawan, Andrew E Hendifar, Michele Maio, Taofeek K Owonikoko, Miguel Quintela-Fandino, Ronnie Shapira-Frommer, Sanatan Saraf, Ping Qiu, Fan Jin, Alexander Gozman, Douglas A Levine

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A195-A196; DOI: 10.1136/jitc-2020-SITC2020.0318

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages